Aspirin resistance in patients with acute coronary events: Risk factors and prevalence as determined by whole blood multiple electrode aggregometry

Pakistan Journal of Medical Sciences

Volumn 29, Issue 6, 2013, Pages

  Ibrahim, O ^a   Maskon, O ^a   Darinah, Noor ^a   Raymond, A A ^a   Rahman, M M ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Aspirin resistance; Aspirin responsiveness; First ever coronary event; Multiplate ; Platelet analyzer; Recurrent coronary event

Indexed keywords

ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ARTICLE; ASPIRIN RESISTANCE; BLOOD CLOTTING TEST; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; PREDICTIVE VALUE; RECURRENT DISEASE; THROMBOCYTE FUNCTION ANALYZER; WHOLE BLOOD MULTIPLE ELECTRODE AGGREGOMETRY;

EID: 84884881577     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.296.3608     Document Type: Article

References (20)

1. Anon. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6921):81-106.
2. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am CollCardiol 2003;41(6):961-965.
3. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142(5):370-380.
4. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195-198.
5. von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate. Hamostaseologie. 2007;27(3):155-160; quiz 61-2.
6. Rahe-Meyer N, Winterhalter M, Hartmann J, Pattison A, Hecker H, Calatzis A, et al. An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting. AnesthAnalg. 2008;107(6):1791-1797.
7. Jambor C, Weber CF, Lau A, Spannagl M, Zwissler B. Multiple electrode aggregometry for ex-vivo detection of the anti-platelet effect of non-opioid analgesic drugs. ThrombHaemost. 2009;101(1):207-209.
8. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. ThrombHaemost. 2008;99(1):121-126.
9. Velik-Salchner C, Maier S, Innerhofer P, Streif W, Klingler A, Kolbitsch C, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. AnesthAnalg. 2008;107(6):1798-1806.
10. Sibbing D, Busch G, Braun S, Sibbing D, Busch G, Braun SN, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J. 2008;29(12):1504-1509.
11. Ibrahim O, Oteh M.A., Syukur A, Che Hassan HHS., Fadilah W, Rahman MM. Evaluation of Aspirin and Clopidogrel resistance in patients with Acute Coronary Syndrome by using Adenosine Diposphate Test and Aspirin Test. Pak J Med Sci. 2013;29(1):97-102.
12. Jambor C, Weber CF, Gerhardt K, Dietrich W, Spannagl M, Heindl B, et al. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. AnesthAnalg. 2009;109(1):25-31.
13. Gum PA, Kottke-Marchant K, Poggio ED, Gum H, Welsh PA, Brook L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-235.
14. Tarjan J, Salamon A, Jager R, Poor F, Barczi V, Dinnyes J, et al. The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil. 1999;140(42):2339-2343.
15. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25(12):2331-2336.
16. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am CollCardiol. 2005;46:1705-1709.
17. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. ThrombHaemost. 1997;78(3):1003-1007.
18. Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ. 2003;326(7380):82-83.
19. Akoglu H, Agbaht K, Piskinpasa S, Falay MY, Dede F, Ozet G, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant. 2012;27(4):1460-1466.
20. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood CoagulFibrinolysis. 2008;19(3):235-239.